Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet for Vitiligo

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Vitiligo+1 MorePhototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet - Device
Eligibility
18 - 100
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at the effects of Narrow band UVB (NB-UVB) treatment on protein expression and histological changes in skin from participants with Vitiligo.

Eligible Conditions
  • Vitiligo
  • Skin Conditions

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
Molecular changes from NB-UVB therapy

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Phototherapy (NB-UVB)
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet · No Placebo Group · N/A

Phototherapy (NB-UVB)
Device
Experimental Group · 1 Intervention: Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,073 Previous Clinical Trials
31,017,205 Total Patients Enrolled
1 Trials studying Vitiligo
2 Patients Enrolled for Vitiligo
Noori Kim, M.DPrincipal InvestigatorJohns Hopkins University

Eligibility Criteria

Age 18 - 100 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to understand the consent procedure.

Who else is applying?

What state do they live in?
Tennessee50.0%
District of Columbia50.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Johns Hopkins Outpatient Center100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?
1100.0%